Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2001 2
2002 2
2003 2
2004 2
2005 1
2007 5
2008 8
2009 4
2010 8
2011 8
2012 14
2013 18
2014 12
2015 11
2016 11
2017 15
2018 27
2019 19
2020 25
2021 30
2022 55
2023 51
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, Prajapati VH, Lio P, Hu X, Wu T, Liu J, Ladizinski B, Chu AD, Eyerich K. Blauvelt A, et al. Among authors: prajapati vh. JAMA Dermatol. 2021 Sep 1;157(9):1047-1055. doi: 10.1001/jamadermatol.2021.3023. JAMA Dermatol. 2021. PMID: 34347860 Free PMC article. Clinical Trial.
Expert consensus on the systemic treatment of atopic dermatitis in special populations.
Adam DN, Gooderham MJ, Beecker JR, Hong CH, Jack CS, Jain V, Lansang P, Lynde CW, Papp KA, Prajapati VH, Turchin I, Yeung J. Adam DN, et al. Among authors: prajapati vh. J Eur Acad Dermatol Venereol. 2023 Jun;37(6):1135-1148. doi: 10.1111/jdv.18922. Epub 2023 Feb 8. J Eur Acad Dermatol Venereol. 2023. PMID: 36695072 Review.
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
Blauvelt A, Ladizinski B, Prajapati VH, Laquer V, Fischer A, Eisman S, Hu X, Wu T, Calimlim BM, Kaplan B, Liu Y, Teixeira HD, Liu J, Eyerich K. Blauvelt A, et al. Among authors: prajapati vh. J Am Acad Dermatol. 2023 Sep;89(3):478-485. doi: 10.1016/j.jaad.2023.05.033. Epub 2023 May 23. J Am Acad Dermatol. 2023. PMID: 37230366 Free article. Clinical Trial.
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.
Paller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, Lio P, Thyssen JP, Simpson EL, Platt AM, Raymundo EM, Liu J, Calimlim BM, Huang X, Gu Y, Hu X, Yang Y, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Paller AS, et al. Among authors: prajapati vh. JAMA Dermatol. 2023 May 1;159(5):526-535. doi: 10.1001/jamadermatol.2023.0391. JAMA Dermatol. 2023. PMID: 37043227 Free PMC article. Clinical Trial.
Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials.
Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, Jiang P, Liu J, Prajapati VH, Simpson EL, Vigna N, Teixeira HD, Barbarot S. Mendes-Bastos P, et al. Among authors: prajapati vh. J Am Acad Dermatol. 2022 Oct;87(4):784-791. doi: 10.1016/j.jaad.2022.06.012. Epub 2022 Jun 15. J Am Acad Dermatol. 2022. PMID: 35714786 Free article. Clinical Trial.
Editorial: Plant products for antiviral therapeutics.
Mandal A, Hazra B, Prajapati VK, Moundipa PF. Mandal A, et al. Among authors: prajapati vk. Front Pharmacol. 2022 Oct 17;13:1039183. doi: 10.3389/fphar.2022.1039183. eCollection 2022. Front Pharmacol. 2022. PMID: 36324673 Free PMC article. No abstract available.
Interleukin-17-A multifaceted cytokine in viral infections.
Sahu U, Biswas D, Prajapati VK, Singh AK, Samant M, Khare P. Sahu U, et al. Among authors: prajapati vk. J Cell Physiol. 2021 Dec;236(12):8000-8019. doi: 10.1002/jcp.30471. Epub 2021 Jun 16. J Cell Physiol. 2021. PMID: 34133758 Free PMC article. Review.
MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies.
Panda M, Kalita E, Singh S, Kumar K, Rao A, Prajapati VK. Panda M, et al. Among authors: prajapati vk. Life Sci. 2022 Sep 15;305:120761. doi: 10.1016/j.lfs.2022.120761. Epub 2022 Jul 1. Life Sci. 2022. PMID: 35787998 Free PMC article. Review.
285 results